Abstract:AllergyEarly View LETTER Associations of tenascin C with Th2 response, edema degree, and disease severity in patients with chronic rhinosinusitis with nasal polyps Min Wang, Min Wang Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China Beijing Laboratory of Allergic Diseases, Beijing Municipal Education Commission, Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, ChinaSearch for more papers by this authorHaiyang Meng, Haiyang Meng Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, ChinaSearch for more papers by this authorNan Zhang, Nan Zhang Upper Airways Research Laboratory, Department of Oto-Rhino-Laryngology, Ghent University Hospital, Ghent, BelgiumSearch for more papers by this authorJian Jiao, Jian Jiao Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China Beijing Laboratory of Allergic Diseases, Beijing Municipal Education Commission, Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, ChinaSearch for more papers by this authorYifei Wang, Yifei Wang Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, ChinaSearch for more papers by this authorMengdi Liu, Mengdi Liu Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, ChinaSearch for more papers by this authorYing Li, Ying Li Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China Beijing Laboratory of Allergic Diseases, Beijing Municipal Education Commission, Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, ChinaSearch for more papers by this authorXiangdong Wang, Corresponding Author Xiangdong Wang [email protected] Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China Beijing Laboratory of Allergic Diseases, Beijing Municipal Education Commission, Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China Correspondence Luo Zhang, Department of Otolaryngology Head and Neck surgery and Department of Allergy, Beijing TongRen Hospital, Capital Medical University, No.1, DongJiaoMinXiang, DongCheng District, Beijing 100730, China. Email: [email protected] Xiangdong Wang, Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, No. 1, DongjiaoMinxiang, Dongcheng District, Beijing 100730, China. Email: [email protected]Search for more papers by this authorLuo Zhang, Corresponding Author Luo Zhang [email protected] orcid.org/0000-0002-0910-9884 Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China Beijing Laboratory of Allergic Diseases, Beijing Municipal Education Commission, Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing, China Correspondence Luo Zhang, Department of Otolaryngology Head and Neck surgery and Department of Allergy, Beijing TongRen Hospital, Capital Medical University, No.1, DongJiaoMinXiang, DongCheng District, Beijing 100730, China. Email: [email protected] Xiangdong Wang, Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, No. 1, DongjiaoMinxiang, Dongcheng District, Beijing 100730, China. Email: [email protected]Search for more papers by this authorClaus Bachert, Claus Bachert orcid.org/0000-0003-4742-1665 Department of Otorhinolaryngology, Head and Neck Surgery, University of Muenster, Muenster, GermanySearch for more papers by this author Min Wang, Min Wang Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China Beijing Laboratory of Allergic Diseases, Beijing Municipal Education Commission, Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, ChinaSearch for more papers by this authorHaiyang Meng, Haiyang Meng Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, ChinaSearch for more papers by this authorNan Zhang, Nan Zhang Upper Airways Research Laboratory, Department of Oto-Rhino-Laryngology, Ghent University Hospital, Ghent, BelgiumSearch for more papers by this authorJian Jiao, Jian Jiao Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China Beijing Laboratory of Allergic Diseases, Beijing Municipal Education Commission, Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, ChinaSearch for more papers by this authorYifei Wang, Yifei Wang Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, ChinaSearch for more papers by this authorMengdi Liu, Mengdi Liu Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, ChinaSearch for more papers by this authorYing Li, Ying Li Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China Beijing Laboratory of Allergic Diseases, Beijing Municipal Education Commission, Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, ChinaSearch for more papers by this authorXiangdong Wang, Corresponding Author Xiangdong Wang [email protected] Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China Beijing Laboratory of Allergic Diseases, Beijing Municipal Education Commission, Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China Correspondence Luo Zhang, Department of Otolaryngology Head and Neck surgery and Department of Allergy, Beijing TongRen Hospital, Capital Medical University, No.1, DongJiaoMinXiang, DongCheng District, Beijing 100730, China. Email: [email protected] Xiangdong Wang, Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, No. 1, DongjiaoMinxiang, Dongcheng District, Beijing 100730, China. Email: [email protected]Search for more papers by this authorLuo Zhang, Corresponding Author Luo Zhang [email protected] orcid.org/0000-0002-0910-9884 Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China Beijing Laboratory of Allergic Diseases, Beijing Municipal Education Commission, Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing, China Correspondence Luo Zhang, Department of Otolaryngology Head and Neck surgery and Department of Allergy, Beijing TongRen Hospital, Capital Medical University, No.1, DongJiaoMinXiang, DongCheng District, Beijing 100730, China. Email: [email protected] Xiangdong Wang, Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, No. 1, DongjiaoMinxiang, Dongcheng District, Beijing 100730, China. Email: [email protected]Search for more papers by this authorClaus Bachert, Claus Bachert orcid.org/0000-0003-4742-1665 Department of Otorhinolaryngology, Head and Neck Surgery, University of Muenster, Muenster, GermanySearch for more papers by this author First published: 17 January 2024 https://doi.org/10.1111/all.16015Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Open Research DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request. Supporting Information Filename Description all16015-sup-0001-DataS1.docxWord 2007 document , 32 KB Data S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. REFERENCES 1Lee K, Tai J, Lee SH, Kim TH. Advances in the knowledge of the underlying airway remodeling mechanisms in chronic Rhinosinusitis based on the Endotypes: a review. Int J Mol Sci. 2021; 22(2): 910. 10.3390/ijms22020910 CASPubMedWeb of Science®Google Scholar 2Wang M, Wang X, Zhang N, et al. Association of periostin expression with eosinophilic inflammation in nasal polyps. J Allergy Clin Immunol. 2015; 136(6): 1700-1703.e9. 10.1016/j.jaci.2015.09.005 CASPubMedWeb of Science®Google Scholar 3Song L, Wang L, Li F, et al. Bone marrow-derived tenascin-C attenuates cardiac hypertrophy by controlling inflammation. J Am Coll Cardiol. 2017; 70(13): 1601-1615. 10.1016/j.jacc.2017.07.789 CASPubMedWeb of Science®Google Scholar 4Kawelke N, Vasel M, Sens C, Au A, Dooley S, Nakchbandi IA. Fibronectin protects from excessive liver fibrosis by modulating the availability of and responsiveness of stellate cells to active TGF-β. PLoS One. 2011; 6(11):e28181. 10.1371/journal.pone.0028181 CASPubMedWeb of Science®Google Scholar 5Fujimoto M, Shiba M, Kawakita F, et al. Deficiency of tenascin-C and attenuation of blood-brain barrier disruption following experimental subarachnoid hemorrhage in mice. J Neurosurg. 2016; 124(6): 1693-1702. 10.3171/2015.4.JNS15484 CASPubMedWeb of Science®Google Scholar 6Cehofski LJ, Kojima K, Terao N, et al. Aqueous fibronectin correlates with severity of macular edema and visual acuity in patients with branch retinal vein occlusion: a proteome study. Invest Ophthalmol Vis Sci. 2020; 61(14): 6. 10.1167/iovs.61.14.6 CASPubMedWeb of Science®Google Scholar 7Du K, Wang M, Zhang N, et al. Involvement of the extracellular matrix proteins periostin and tenascin C in nasal polyp remodeling by regulating the expression of MMPs. Clin Transl Allergy. 2021; 11(7):e12059. 10.1002/clt2.12059 CASPubMedWeb of Science®Google Scholar 8Wang M, Zhang N, Zheng M, et al. Cross-talk between TH2 and TH17 pathways in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2019; 144(5): 1254-1264. 10.1016/j.jaci.2019.06.023 CASPubMedWeb of Science®Google Scholar 9Wang C, Lou H, Wang X, et al. Effect of budesonide transnasal nebulization in patients with eosinophilic chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2015; 135(4): 922-929.e6. 10.1016/j.jaci.2014.10.018 CASPubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation

Abstract:Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous disease characterized by a defective immune barrier and massive inflammatory cell infiltration.E4Lou H. Meng Y. Piao Y. Wang C. Zhang L. Bachert C. Predictive significance of tissue eosinophilia for nasal polyp recurrence in the Chinese population.Am J Rhinol Allergy. 2015; 29: 350-356Crossref PubMed Scopus (124) Google Scholar, 1Wang H. Li Z.Y. Jiang W.X. Liao B. Zhai G.T. Wang N. et al.The activation and function of IL-36γ in neutrophilic inflammation in chronic rhinosinusitis.J Allergy Clin Immunol. 2018; 141: 1646-1658Abstract Full Text Full Text PDF PubMed Scopus (69) Google Scholar, 2Lu H. Lin X.S. Yao D.M. Zhuang Y.Y. Wen G.F. Shi J. et al.Increased serum amyloid A in nasal polyps is associated with systemic corticosteroid insensitivity in patients with chronic rhinosinusitis with nasal polyps: a pilot study.Eur Arch Otorhinolaryngol. 2018; 275: 401-408Google Scholar Currently, the most effective medical therapy in clinical practice is the use of glucocorticoids.E1Fokkens W.J. Lund V.J. Mullol J. Bachert C. Alobid I. Baroody F. et al.EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists.Rhinology. 2012; 50: 1-12Crossref PubMed Google Scholar, 3Wen W. Liu W. Zhang L. Bai J. Fan Y. Xia W. et al.Increased neutrophilia in nasal polyps reduces the response to oral corticosteroid therapy.J Allergy Clin Immunol. 2012; 129: 1522-1528Abstract Full Text Full Text PDF PubMed Scopus (195) Google Scholar, 4Wang C. Lou H. Wang X. Wang Y. Fan E. Li Y. et al.Effect of budesonide transnasal nebulization in patients with eosinophilic chronic rhinosinusitis with nasal polyps.J Allergy Clin Immunol. 2015; 135: 922-929Abstract Full Text Full Text PDF PubMed Scopus (72) Google Scholar, 5Milara J. Morell A. Ballester B. Armengot M. Morcillo E. Cortijo J. MUC4 impairs the anti-inflammatory effects of corticosteroids in patients with chronic rhinosinusitis with nasal polyps.J Allergy Clin Immunol. 2017; 139: 855-862Abstract Full Text Full Text PDF PubMed Scopus (27) Google Scholar However, many patients have a poor response to the therapy.1Wang H. Li Z.Y. Jiang W.X. Liao B. Zhai G.T. Wang N. et al.The activation and function of IL-36γ in neutrophilic inflammation in chronic rhinosinusitis.J Allergy Clin Immunol. 2018; 141: 1646-1658Abstract Full Text Full Text PDF PubMed Scopus (69) Google Scholar, 4Wang C. Lou H. Wang X. Wang Y. Fan E. Li Y. et al.Effect of budesonide transnasal nebulization in patients with eosinophilic chronic rhinosinusitis with nasal polyps.J Allergy Clin Immunol. 2015; 135: 922-929Abstract Full Text Full Text PDF PubMed Scopus (72) Google Scholar, 5Milara J. Morell A. Ballester B. Armengot M. Morcillo E. Cortijo J. MUC4 impairs the anti-inflammatory effects of corticosteroids in patients with chronic rhinosinusitis with nasal polyps.J Allergy Clin Immunol. 2017; 139: 855-862Abstract Full Text Full Text PDF PubMed Scopus (27) Google Scholar Thus, developing biomarkers predicting glucocorticoid response in patients with CRSwNP would greatly improve the efficacy of glucocorticoids and lighten the economic burden in clinical practice. Although several biomarkers associated with glucocorticoid resistance have been discovered recently, most of these have been detected in polyp tissue samples.6Hong H. Chen F. Sun Y. Yang Q. Gao W. Cao Y. et al.Nasal IL-25 predicts the response to oral corticosteroids in chronic rhinosinusitis with nasal polyps.J Allergy Clin Immunol. 2018; 141: 1890-1892Abstract Full Text Full Text PDF PubMed Scopus (19) Google Scholar, 7Yao Y. Xie S. Yang C. Zhang J. Wu X. Sun H. Biomarkers in the evaluation and management of chronic rhinosinusitis with nasal polyposis.Eur Arch Otorhinolaryngol. 2017; 274: 3559-3566Crossref PubMed Scopus (31) Google Scholar Because the procedure for obtaining tissues often leads to unavoidable mucosal trauma and increased risk of bleeding and infection, there is a need for biomarkers that can be detected by using noninvasive procedures. Charcot-Leyden crystal (CLC) was first described in the 19th century.8Dor P.J. Ackerman S.J. Gleich G.J. Charcot-Leyden crystal protein and eosinophil granule major basic protein in sputum of patients with respiratory diseases.Am Rev Respir Dis. 1984; 130: 1072-1077PubMed Google Scholar It is a unique component of eosinophils and basophils and is regarded as a hallmark protein of eosinophilic inflammatory diseases. Previous studies have demonstrated the presence of CLC in sputum of patients given a diagnosis of allergic asthma or pulmonary ascariasis and in the feces of patients with eosinophilic diseases of the digestive system, such as ulcerative colitis and amoebic Trichuris species infection.8Dor P.J. Ackerman S.J. Gleich G.J. Charcot-Leyden crystal protein and eosinophil granule major basic protein in sputum of patients with respiratory diseases.Am Rev Respir Dis. 1984; 130: 1072-1077PubMed Google Scholar In preliminary experiments we successfully detected CLC in nasal secretions of patients with CRSwNP collected according to the noninvasive method of Watelet et al.9Watelet J.B. Gevaert P. Holtappels G. Van Cauwenberge P. Bachert C. Collection of nasal secretions for immunological analysis.Eur Arch Otorhinolaryngol. 2004; 261: 242-246Crossref PubMed Scopus (45) Google Scholar Because rhinorrhea is one of the most common symptoms in these patients and these secreted fluids can readily be collected by using a noninvasive method, we have hypothesized that CLC in nasal secretions might serve as a predictive marker of glucocorticoid response in patients with CRSwNP. Thus this study aimed to investigate the predictive capacity of CLC concentrations in nasal secretions for glucocorticoid response in patients with CRSwNP. The study was approved by the Ethics Committee of Beijing TongRen Hospital, and all participants provided written informed consent. Eighty-nine patients given a diagnosis of CRSwNP according to the European Position Paper on Rhinosinusitis and Nasal Polyps 2012E1Fokkens W.J. Lund V.J. Mullol J. Bachert C. Alobid I. Baroody F. et al.EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists.Rhinology. 2012; 50: 1-12Crossref PubMed Google Scholar and who had no contraindications to glucocorticoids were enrolled in the study. None of the patients had received any treatment with glucocorticoids or immunomodulatory drugs within 4 weeks before enrollment. Patients with fungal sinusitis, allergic fungal rhinosinusitis, cystic fibrosis, or primary ciliary dyskinesia were excluded from the study, and all eligible patients were evaluated for comorbidity of allergic rhinitis, asthma, and atopy. None of the enrolled patients received a diagnosis of aspirin-exacerbated respiratory disease. Clinical characteristics, such as staging of computed tomography (CT) and objective evaluation of olfactory function, were determined, as described previously (detailed criteria for each clinical characteristics are presented in the Patients and samples section in this article's Online Repository at www.jacionline.org).E1Fokkens W.J. Lund V.J. Mullol J. Bachert C. Alobid I. Baroody F. et al.EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists.Rhinology. 2012; 50: 1-12Crossref PubMed Google Scholar, E2Bousquet J. Khaltaev N. Cruz A.A. Denburg J. FokkenWJ Togias A. et al.Allergic rhinitis and its impact on asthma (ARIA) 2008.Allergy. 2008; 63: 8-160Crossref PubMed Scopus (3670) Google Scholar, E3Global Initiative For Asthma. Global strategy for asthma management and prevention, Revised 2014 Vancouver, GINA, 2014. Available at: www.ginasthma.orgGoogle Scholar, E4Lou H. Meng Y. Piao Y. Wang C. Zhang L. Bachert C. Predictive significance of tissue eosinophilia for nasal polyp recurrence in the Chinese population.Am J Rhinol Allergy. 2015; 29: 350-356Crossref PubMed Scopus (124) Google Scholar, E5Lund V. Kennedy D. Staging for rhinosinusitis.Otolaryngol Head Neck Surg. 1997; 117: S35-S40Crossref PubMed Scopus (778) Google Scholar, E6Meng Y. Lou H. Wang C. Zhang L. Predictive significance of computed tomography in eosinophilic chronic rhinosinusitis with nasal polyps.Int Forum Allergy Rhinol. 2016; 6: 812-819Crossref PubMed Scopus (45) Google Scholar Bilateral nasal cavity secretions and polyp tissues were collected for comparison from each patient on admission to the hospital, as described previously (detailed information on collection of nasal secretions is presented in the Patients and samples section in this article's Online Repository).9Watelet J.B. Gevaert P. Holtappels G. Van Cauwenberge P. Bachert C. Collection of nasal secretions for immunological analysis.Eur Arch Otorhinolaryngol. 2004; 261: 242-246Crossref PubMed Scopus (45) Google Scholar After enrollment, all patients started a 2-week course of oral glucocorticoid therapy (24 mg of methylprednisolone by mouth every morning) and at the end of this treatment period were divided into 2 groups according to the Nasal Polyp Size Score (NPSS) system (see Table E1 in this article's Online Repository at www.jacionline.org): glucocorticoid responders (n = 48, patients whose change in NPSS was more than 1 point) and glucocorticoid nonresponders (n = 41, patients whose change in NPSS was no more than 1 point). Data for the clinical characteristics for each patient were expressed as medians and interquartile ranges (IQRs), except for binary variables and age (expressed as the mean and SD, see Table E2 in this article's Online Repository at www.jacionline.org). CLC concentrations in nasal secretions were analyzed by using an ELISA. Statistical analysis was performed with GraphPad Prism 6 software (GraphPad Software, La Jolla, Calif), and receiver operating characteristic (ROC) curves were drawn with SPSS 24.0 (IBM, Armonk, NY; details are presented in the Methods section in this article's Online Repository). Statistical significance was considered at a P value of less than .05. The 2 groups were not significantly different in terms of sex, age, smoking history, nasal obstruction, rhinorrhea, facial pain, or subjective olfactory disorder. However, patients in the glucocorticoid responder group had higher rates of comorbid allergic rhinitis (P = .025; odds ratio [OR], 3.600; 95% CI, 1.184-10.94) and atopy (P = .020; OR, 2.824; 95% CI, 1.190-6.699) than patients in the glucocorticoid nonresponder group. Similarly, patients in the glucocorticoid responder group had significantly greater severity of olfactory disorders (P = .035), greater total ethmoid sinus score/total maxillary sinus score (E/M) ratios of Lund-Mackay scores (P < .001),E6Meng Y. Lou H. Wang C. Zhang L. Predictive significance of computed tomography in eosinophilic chronic rhinosinusitis with nasal polyps.Int Forum Allergy Rhinol. 2016; 6: 812-819Crossref PubMed Scopus (45) Google Scholar and greater percentages of peripheral blood eosinophils (P = .016) than patients in the glucocorticoid nonresponder group. There was no significant difference in neutrophil percentages between the 2 groups (P = .172). Histologic evaluation of polyp tissue revealed that patients in the glucocorticoid responder group had significantly greater numbers of infiltrating eosinophils (P < .001) and lower numbers of infiltrating neutrophils (P < .001) compared with patients in the glucocorticoid nonresponder group. Analysis of the average concentration of CLC in nasal secretions showed that this was significantly greater (105.3 ng/mL; IQR, 51.08-153.5 ng/mL) in patients in the glucocorticoid responder group than in patients in the glucocorticoid nonresponder group (0.6460 ng/mL; IQR, 0-29.34 ng/mL; P < .001; see Table E2). Four patients in the glucocorticoid responder group had much higher CLC concentrations (outliers are marked red in Fig 1, B; with 3 being 1000 ng/mL and 1 being 651.8 ng/mL). Despite excluding these data, differences between median values (90.02 ng/mL; IQR, 50.18-136.3 ng/mL) for the glucocorticoid responder group were still found to be significantly greater than for those of the glucocorticoid nonresponder group (P < .001). A binary logistic regression model method of forward Wald mode was used for further comparison between groups to determine specific factors associated with polyp recurrence. All the clinical characteristics, including CLC concentrations in nasal secretions; percentages of eosinophils, neutrophils, lymphocytes, and plasma cells in polyp tissues; percentages of eosinophils in peripheral blood; Lund-Mackay score E/M ratios; objective olfactory function; and comorbid rates of allergic rhinitis and atopy, which had been found to be significantly different by preliminary analyses, were introduced as variables in the binary logistic regression model method. The multivariate analysis revealed that only CLC concentrations in nasal secretions (P < .001; OR, 1.043; 95% CI, 1.020-1.066) and eosinophil percentages in polyp tissues (P < .001; OR, 1.056; 95% CI, 1.025-1.087) showed the potential for predicting glucocorticoid response in patients with CRSwNP (see Table E3 in this article's Online Repository at www.jacionline.org). ROC curves for these 2 parameters (shown in Fig 1, A) demonstrated corresponding areas under the curve to be 0.897 and 0.855 for CLC concentrations in nasal secretions and eosinophil percentages in polyp tissues, respectively. According to the Youden index (see Table E4 in this article's Online Repository at www.jacionline.org), the optimal cutoff value for CLC concentrations in nasal secretions to predict glucocorticoid response was 30.065 ng/mL (Youden index = 67.6%, with a sensitivity of 89.6% and a specificity of 78.0%; Fig 1, B), and the optimal cutoff value for percentage of eosinophils in polyp tissues to predict glucocorticoid response was 41.50% (Youden index = 66.6%, with a sensitivity of 81.3% and a specificity of 85.4%; Fig 1, C). In regard to the effect on glucocorticoids, NPSSs of glucocorticoid responders and glucocorticoid nonresponders demonstrated no difference before glucocorticoid treatment (P = .968), but there were significant differences in NPSSs of postglucocorticoid treatment (P < .001) and change in NPSSs before and after glucocorticoid therapy (P < .001). Analysis of CLC concentrations in 29 patients (12 of whom were glucocorticoid responders and 17 of whom were glucocorticoid nonresponders) with available samples indicated that CLC was detectable in both subgroups before and after glucocorticoid treatment and that glucocorticoid treatment significantly decreased CLC concentrations in the glucocorticoid responder group (P = .002) but not in the glucocorticoid nonresponder group (P = .211; Fig 1, D and E). Additional analysis of results for CLC concentrations indicated that patients with CLC concentrations of less than 30.065 ng/mL (n = 37) showed significantly greater differences in response to glucocorticoid therapy compared with those in patients with CLC concentrations of greater than the cutoff value (n = 52; P < .001; Fig 2, A). Although the NPSS was not significantly different between the 2 groups before glucocorticoid therapy (P > .999), this was significantly decreased after glucocorticoid therapy in patients with higher CLC concentrations compared with patients with lower CLC concentrations (P < .001; Fig 2, B and C). Moreover, patients with greater CLC concentrations in nasal secretions displayed more severe infiltration of eosinophils in both polyp tissues (P < .001) and peripheral blood than patients with lower CLC concentrations (P = .014; Fig 2, D and E), whereas infiltration of neutrophils was not significantly different in either polyp tissues (P = .302) or peripheral blood (P = .071) of patients between the 2 groups (Fig 2, F and G). In contrast, CLC concentrations in nasal secretions were not significantly associated with distribution of sex, age, smoking history, comorbid asthma, rhinitis, or atopy (see Fig E1 in this article's Online Repository at www.jacionline.org). Similarly, any of the 4 subjective symptoms (see Fig E2 in this article's Online Repository at www.jacionline.org), objective olfactory test results, Lund-Mackay scores of the paranasal sinuses, or E/M ratios (see Fig E3 in this article's Online Repository at www.jacionline.org) were also not significantly associated with CLC concentrations in patients with CRSwNP. In this study we investigated the predictive significance of CLC concentrations in nasal secretions for glucocorticoid response in patients with CRSwNP and found that this noninvasive sampling method had a similar predictive capacity as measuring eosinophil percentages in polyp tissues. CLC concentrations in nasal secretions were associated with glucocorticoid responses, and glucocorticoid therapy significantly decreased CLC concentrations. Nevertheless, all the other parameters, including sex, age, smoking history, comorbid asthma, comorbid allergic rhinitis, comorbid atopy, symptom severity, or CT scan staging, had little effect on CLC concentrations in nasal secretions. Also, CLC concentrations in nasal secretions were correlated with eosinophil percentages in tissue polyps (Spearman correlation model: P < .001, R = 0.5). The possibility that nasal secretions are as valuable as polyp tissues for predicting glucocorticoid response in patients with CRSwNP is particularly important because collection of nasal secretions is much easier, safer, and more tolerable than collection of polyp tissues, and the risks of trauma and hemorrhage are lower. Additionally, use of nasal secretions is an efficient and accurate method of both detecting and counting various inflammatory cells. In the case of the 4 glucocorticoid responders with much greater nasal CLC concentrations (outliers) than the rest of the group (marked red in Fig 2, B), further analysis demonstrated that in these patients the clinical indices of eosinophil percentages in polyp tissues, comorbidity of asthma and allergic rhinitis, or inflammatory cell percentages in tissue polyps were not significantly different compared with those of the other patients in the group. Considering the efficacy and accuracy of glucocorticoid therapy, it is important to predict the glucocorticoid response of patients before administration of glucocorticoid therapy for long periods. Furthermore, predicting the response to glucocorticoid therapy in patients with CRSwNP is particularly important because glucocorticoid insensitivity is often observed in a large number of this group of patients. In this regard our finding that 46.1% (41/89) of patients with CRSwNP were insensitive to glucocorticoid therapy is in accordance with the findings of a more recent study by Hong et al,6Hong H. Chen F. Sun Y. Yang Q. Gao W. Cao Y. et al.Nasal IL-25 predicts the response to oral corticosteroids in chronic rhinosinusitis with nasal polyps.J Allergy Clin Immunol. 2018; 141: 1890-1892Abstract Full Text Full Text PDF PubMed Scopus (19) Google Scholar which reported 44.2% (23/52) of patients with CRSwNP to be nonresponsive to glucocorticoid therapy and demonstrates that CLC concentration in nasal secretions is likely to be a suitable biomarker for predicting glucocorticoid response for patients with CRSwNP. Recently, several studies have indicated different biomarkers that might be associated with decreased response to glucocorticoids in patients with CRSwNP.7Yao Y. Xie S. Yang C. Zhang J. Wu X. Sun H. Biomarkers in the evaluation and management of chronic rhinosinusitis with nasal polyposis.Eur Arch Otorhinolaryngol. 2017; 274: 3559-3566Crossref PubMed Scopus (31) Google Scholar For example, increased neutrophilia in nasal polyps3Wen W. Liu W. Zhang L. Bai J. Fan Y. Xia W. et al.Increased neutrophilia in nasal polyps reduces the response to oral corticosteroid therapy.J Allergy Clin Immunol. 2012; 129: 1522-1528Abstract Full Text Full Text PDF PubMed Scopus (195) Google Scholar; increased levels of serum amyloid A, an apolipoprotein associated with high-density lipoprotein2Lu H. Lin X.S. Yao D.M. Zhuang Y.Y. Wen G.F. Shi J. et al.Increased serum amyloid A in nasal polyps is associated with systemic corticosteroid insensitivity in patients with chronic rhinosinusitis with nasal polyps: a pilot study.Eur Arch Otorhinolaryngol. 2018; 275: 401-408Google Scholar; upregulation of mucin 4; and downregulation of mucin 1E7Haruna S. Ohtori N. Moriyama H. Nakanishi M. Olfactory dysfunction in sinusitis with infiltration of numerous activated eosinophils.Auris Nasus Larynx. 2006; 33: 23-30Abstract Full Text Full Text PDF PubMed Scopus (35) Google Scholar, 5Milara J. Morell A. Ballester B. Armengot M. Morcillo E. Cortijo J. MUC4 impairs the anti-inflammatory effects of corticosteroids in patients with chronic rhinosinusitis with nasal polyps.J Allergy Clin Immunol. 2017; 139: 855-862Abstract Full Text Full Text PDF PubMed Scopus (27) Google Scholar and IL-256Hong H. Chen F. Sun Y. Yang Q. Gao W. Cao Y. et al.Nasal IL-25 predicts the response to oral corticosteroids in chronic rhinosinusitis with nasal polyps.J Allergy Clin Immunol. 2018; 141: 1890-1892Abstract Full Text Full Text PDF PubMed Scopus (19) Google Scholar have been associated with glucocorticoid insensitivity. However, all these biomarkers have been investigated in polyp tissues, thus making use of CLC concentrations in nasal secretions a suitable easy and faster alternative for predicting glucocorticoid response in patients with CRSwNP. A major limitation of the present study is that it was conducted in Asian patients, whose response to steroids is poor because of a greater prevalence of noneosinophilic nasal polyps. Therefore the finding for a predictive capability of nasal CLC secretion for nasal polyp response to glucocorticoids is not generalizable to Western patients and needs to be investigated further in this population. Nevertheless, the determination of specific secreted proteins in nasal secretions might serve as a reliable noninvasive biomarker in the future to predict the response of patients with CRSwNP to glucocorticoids. In summary, our study has demonstrated that the CLC concentration in nasal secretions is a suitable noninvasive biomarker that could predict glucocorticoid response for patients with CRSwNP. Routine use of this biomarker in clinical practice might lead to better strategies for glucocorticoid therapy in the future. Eighty-nine patients were given a diagnosis of CRSwNP according to the European Position Paper on Rhinosinusitis and Nasal Polyps 2012,E1Fokkens W.J. Lund V.J. Mullol J. Bachert C. Alobid I. Baroody F. et al.EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists.Rhinology. 2012; 50: 1-12Crossref PubMed Google Scholar scheduled to undergo functional endoscopic sinus surgery in Beijing TongRen Hospital, and enrolled in this study. Patients with contraindications for glucocorticoids or who had used glucocorticoids or immunomodulatory drugs within 4 weeks before the study were excluded. Patients with aspirin-exacerbated respiratory disease, fungal sinusitis, allergic fungal rhinosinusitis, cystic fibrosis, or primary ciliary dyskinesia were also excluded. Allergic rhinitis was diagnosed according to the Allergic Rhinitis and its Impact on Asthma 2008E2Bousquet J. Khaltaev N. Cruz A.A. Denburg J. FokkenWJ Togias A. et al.Allergic rhinitis and its impact on asthma (ARIA) 2008.Allergy. 2008; 63: 8-160Crossref PubMed Scopus (3670) Google Scholar criteria. Asthma was diagnosed as defined by the Global Initiative For Asthma 2014 guidelines.E3Global Initiative For Asthma. Global strategy for asthma management and prevention, Revised 2014 Vancouver, GINA, 2014. Available at: www.ginasthma.orgGoogle Scholar Atopy was evaluated by measurement of serum specific IgE levels (cutoff value, 0.35 kUA/L; Phadia, Uppsala, Sweden). This study was approved by the Ethics Committee of Beijing TongRen Hospital, and all participants provided written informed consent before entry into the study. All eligible patients were asked to self-evaluate their symptoms according to a 0- to 10-point visual analogue scale.E4Lou H. Meng Y. Piao Y. Wang C. Zhang L. Bachert C. Predictive significance of tissue eosinophilia for nasal polyp recurrence in the Chinese population.Am J Rhinol Allergy. 2015; 29: 350-356Crossref PubMed Scopus (124) Google Scholar In addition, all the participants underwent CT scans of the paranasal sinuses, and the outcomes of CT scans were evaluated by using the Lund-Mackay staging system.E5Lund V. Kennedy D. Staging for rhinosinusitis.Otolaryngol Head Neck Surg. 1997; 117: S35-S40Crossref PubMed Scopus (778) Google Scholar, E6Meng Y. Lou H. Wang C. Zhang L. Predictive significance of computed tomography in eosinophilic chronic rhinosinusitis with nasal polyps.Int Forum Allergy Rhinol. 2016; 6: 812-819Crossref PubMed Scopus (45) Google Scholar The objective olfactory test was performed as described by Haruna et al.E7Haruna S. Ohtori N. Moriyama H. Nakanishi M. Olfactory dysfunction in sinusitis with infiltration of numerous activated eosinophils.Auris Nasus Larynx. 2006; 33: 23-30Abstract Full Text Full Text PDF PubMed Scopus (35) Google Scholar Endoscopic examinations were conducted to investigate the polyp size of each side of the nasal cavity.E8Milara J. Peiró T. Armengot M. Frias S. Morell A. Serrano A. et al.Mucin 1 downregulation associates with corticosteroid resistance in chronic rhinosinusitis with nasal polyps.J Allergy Clin Immunol. 2015; 135: 470-476Abstract Full Text Full Text PDF PubMed Scopus (48) Google Scholar Endoscopic images were evaluated and scored independently by 2 otolaryngologists who were blinded to the trial design. As a result of the examination, all the patients scored at least 4 in total before the glucocorticoid therapy was undertaken. Peripheral blood data were obtained from a routine blood test. On admission to the hospital, bilateral nasal cavity secretions from each patient were collected by the method described by Watelet et al.E9Watelet J.B. Gevaert P. Holtappels G. Van Cauwenberge P. Bachert C. Collection of nasal secretions for immunological analysis.Eur Arch Otorhinolaryngol. 2004; 261: 242-246Crossref PubMed Scopus (61) Google Scholar Each sample was diluted with 0.5 mL of 0.9% natural saline and kept at room temperature for 1 hour, after which samples were centrifuged into a Falcon tube and stored at 4°C until further measurements. Polyp tissues (3 × 3 mm for each participant) were also obtained immediately after nasal secretions were collected. The patients received a 2-week therapy of oral glucocorticoid (24 mg of methylprednisolone by mouth every morning) and at the end of treatment were divided into glucocorticoid responder (n = 48) and glucocorticoid nonresponder (n = 41) groups based on the change in polyp size scores. Patients who did not have a reduction of more than 1 polyp score based on the NPSS system after glucocorticoid therapy were defined as glucocorticoid nonresponders.E1Fokkens W.J. Lund V.J. Mullol J. Bachert C. Alobid I. Baroody F. et al.EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists.Rhinology. 2012; 50: 1-12Crossref PubMed Google Scholar, E8Milara J. Peiró T. Armengot M. Frias S. Morell A. Serrano A. et al.Mucin 1 downregulation associates with corticosteroid resistance in chronic rhinosinusitis with nasal polyps.J Allergy Clin Immunol. 2015; 135: 470-476Abstract Full Text Full Text PDF PubMed Scopus (48) Google Scholar Histologic criteria were determined by using hematoxylin and eosin (H&E) staining.E10Fischer A.H. Jacobson K.A. Rose J. Zeller R. Hematoxylin and eosin staining of tissue and cell sections.CSHProtoc. 2008; 2008Google Scholar Tissue samples were dehydrated, embedded in paraffin, and then cut at 5-μm thicknesses by using a Leica RM2235 cryostat (Leica Microsystems, Bannockburn, Ill). All sections were examined by using optical microscopy at a magnification of ×400, and absolute numbers and percentages of eosinophils, neutrophils, plasma cells, and lymphocytes were calculated. For each section, absolute numbers and percentages of each cell type were recorded as mean data of 3 nonoverlapping regions, and the final evaluation for each patient's tissue sample was recorded as mean data of 5 sections. Inflammatory cell counts were performed by 2 pathologists who were blind to the study design. Detection and estimation of CLC concentrations in nasal secretions were performed by using commercial ELISA kits (Cloud-Clone, Wuhan, China). The detection range of this kit was 0.312 to 20 ng/mL CLC. Before the assay, all samples of nasal secretions were diluted 50-fold with 0.9% natural saline, and the assay was conducted strictly according to the manufacturer's instructions. All data were expressed as medians and IQRs, except for binary variables and age, which were expressed as means and SDs. Statistical analysis was performed with GraphPad Prism 6 software. All parametric variants were analyzed by using Student t tests, and nonparametric variants were analyzed by using Mann-Whitney U tests. Binary variables were analyzed by using Fisher and χ2 tests, and binary logistic regression was used to find the potential predictive markers for glucocorticoid response. ROC curves were generated to determine the optimal cutoff point by using SPSS version 24.0. The predictive ability of CLC concentrations in nasal secretions for glucocorticoid sensitivity was determined by the area under the curve, and the optimal cutoff point was determined by using the Youden index. P values of less than .05 were considered statistically significant. All data were analyzed by using 2-tailed tests.Fig E2Severity and incidence of chronic rhinosinusitis symptoms in patients with nasal CLC concentrations less than or greater than the cutoff value: A, nasal obstruction; B, rhinorrhea; C, facial pain; and D, subjective olfactory disorder.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Fig E3Difference of patients with nasal CLC concentrations less than or greater than the cutoff value in objective olfactory test results (A), Lund-Mackay scores for paranasal sinuses on CT scans (B), and ratios of Lund-Mackay scores of ethmoid sinus/Lund Mackay scores of the maxillary sinus (C).View Large Image Figure ViewerDownload Hi-res image Download (PPT)Table E1NPSS systemPolyp scorePolyp size0No polyps1Small polyps in the middle meatus not reaching below the inferior border of the middle concha2Polyps reaching below the lower border of the middle turbinate3Large polyps reaching the lower border of the attachment of inferior turbinate or polyps medial to the middle concha4Large polyps causing almost complete congestion/obstruction of the inferior meatus Open table in a new tab Table E2Demographic and clinical characteristics of glucocorticoid responders and glucocorticoid nonrespondersGlucocorticoid responders (n = 48)Glucocorticoid nonresponders (n = 41)P valueSex (male/female)29/1928/13.510Age (y), mean ± SD44.69 ± 11.5244.63 ± 11.66.983Asthma (yes/no)18/3016/251Allergic rhinitis (yes/no)16/325/36.025Atopy (yes/no)32/1617/24.020Smoking history (yes/no)9/397/341Nasal obstruction, median (IQR)7.0 (6.0-8.0)7.0 (6.0-8.0).895Rhinorrhea, median (IQR)6.0 (4.3-6.8)5.0 (3.5-6.5).101Facial pain, median (IQR)0 (0-2.8)0 (0-2.0).514Subjective olfactory disorder, median (IQR)6.0 (4.0-10.0)4.0 (0-8.5).080Objective olfactory function, median (IQR)5.0 (3.0-5.0)3.0 (1.0-5.0).035Lund-Mackay score, median (IQR)19.5 (14.3-22.0)17.0 (14.0-20.0).154Lund-Mackay score E/M ratio, median (IQR)2.6 (2.0-3.5)2.0 (1.9-2.7)<.001NPSS (preglucocorticoid therapy), median (IQR)5.0 (4.0-6.0)5.0 (4.0-6.0).767NPSS (postglucocorticoid therapy), median (IQR)2.0 (2.0-3.0)5.0 (4.0-5.0)<.001NPSS (postglucocorticoid minus preglucocorticoid), median (IQR)−2.0 (−3.0 to −2.0)0 (−1.0 to 0)<.001Tissue eosinophils (%), median (IQR)60.75 (47.25-74.38)10.52 (0-37.17)<.001Tissue neutrophils (%), median (IQR)0 (0-1.255)1.400 (0-4.600).003Tissue lymphocytes (%), median (IQR)21.50 (13.54-33.30)48.70 (31.96-65.85)<.001Tissue plasma cells (%), median (IQR)14.95 (6.75-21.20)21.30 (9.65-40.15)<.001Peripheral blood eosinophils (%), median (IQR)5.950 (4.625-8.775)4.500 (1.650-7.900).016Peripheral blood neutrophils (%), median (IQR)53.45 (47.30-58.10)56.00 (49.45-63.05).172Nasal secretion eosinophils, median (IQR)1.0 (0-2.0)0 (0-1.0).032Nasal secretion CLC concentration, median (IQR)105.3 (51.08-153.5)0.6460 (0-29.34)<.001 Open table in a new tab Table E3Binary logistic regression for potential markers associated with glucocorticoid responseMarkersOR95% CIP valueCLC concentration (nasal secretions)1.0431.020-1.066<.001Eosinophil percentage (tissue)1.0561.025-1.087<.001 Open table in a new tab Table E4Determination of the optimal cutoff value for each markerCutoff valueSensitivitySpecificityYouden indexCLC concentration (nasal secretions)28.42529.34030.06532.18835.2920.8960.8960.8960.8750.8540.7320.7560.7800.7800.7800.6280.6520.6760.6550.635Eosinophil percentage (tissue)38.87040.50041.50043.00044.5000.8330.8130.8130.7920.7710.8050.8290.8540.8540.8540.6380.6420.6660.6450.624Determination of the optimal cutoff value for each marker is shown in boldface. Open table in a new tab Determination of the optimal cutoff value for each marker is shown in boldface.

Rhinitis, sinusitis, and ocular allergy IFN-l1 enhances Staphylococcus aureus clearance in healthy nasal mucosa but not in nasal polyps

Effects of lysed Enterococcus faecalis FK-23 on experimental allergic rhinitis in a murine model

Ifn-Lambda 1 Enhances Staphylococcus Aureus Clearance In Healthy Nasal Mucosa But Not In Nasal Polyps

IFN-λ1 enhances Staphylococcus aureus clearance in healthy nasal mucosa but not in nasal polyps.

Associations of Tenascin C with Th2 Response, Edema Degree, and Disease Severity in Patients with Chronic Rhinosinusitis with Nasal Polyps.

Role of yes‐associated protein in interleukin‐13 induced nasal remodeling of chronic rhinosinusitis with nasal polyps

Effect of Allergy on Outcomes after Endoscopic Sinus Surgeryin Patients with Chronic Rhinosinusitis

Efficacy of Loratadine Combined with Budesonide Nasal Spray in the Treatment of Allergic Rhinitis and its Effect on Th1/Th2 Cytokines

Topical Therapies for Management of Olfactory Dysfunction in Chronic Rhinosinusitis with Nasal Polyps: Steroid-Eluting Stents

Lactoferrin Administration Into The Nostril Alleviates Murine Allergic Rhinitis And Its Mechanisms

Charcot-Leyden Crystal Concentration in Nasal Secretions Predicts Clinical Response to Glucocorticoids in Patients with Chronic Rhinosinusitis with Nasal Polyps.

Increased nasal mucosal interferon and CCL13 response to a TLR7/8 agonist in asthma and allergic rhinitis

Clinical effectiveness and potential predictability of omalizumab in patients with difficult-to-treat chronic rhinosinusitis with nasal polyps and asthma based on the noninvasive markers – A real-life prospective study

A nationwide survey of otolaryngologists’ compliance with Chinese guidelines for diagnosis and treatment of allergic rhinitis

Effect of Non-allergic Inflammation in Nasal and Pharyngeal Area on Lower Airway Hyperresponsiveness

Clinical study of the combination therapy with intranasal antihistamine and nasal corticosteroids in the treatment of nasal obstruction of persistent non-allergic rhinitis

Increased Nasal IL-5 Levels Act As a Predisposing Factor of Asthma in Southern China.

Effect of Loratadine Tablets in Combination with Other Drugs on Nasal Physiological Function and T Lymphocyte Subsets in Patients with Allergic Rhinitis

Up-regulation of systemic and local BDNF in non-allergic Nasal Polyps in China

Nasal and blood transcriptomic pathways underpinning the clinical response to grass pollen immunotherapy

Protective Effect of Allergen Immunotherapy in Patients With Allergic Rhinitis and Asthma Against COVID-19 Infection: Observational, Nationwide, and Multicenter Study